187 related articles for article (PubMed ID: 34950776)
1. Combination of psoas muscle mass index and neutrophil/lymphocyte ratio as a prognostic predictor for patients undergoing nonsurgical hepatocellular carcinoma therapy.
Sugama Y; Miyanishi K; Osuga T; Tanaka S; Hamaguchi K; Ito R; Sakamoto H; Kubo T; Ohnuma H; Murase K; Takada K; Kobune M; Kato J
JGH Open; 2021 Dec; 5(12):1335-1343. PubMed ID: 34950776
[TBL] [Abstract][Full Text] [Related]
2. Advanced hepatocellular carcinoma treated by transcatheter arterial chemoembolization with drug-eluting beads plus lenvatinib versus sorafenib, a propensity score matching retrospective study.
Xue M; Wu Y; Zhu B; Zou X; Fan W; Li J
Am J Cancer Res; 2021; 11(12):6107-6118. PubMed ID: 35018245
[TBL] [Abstract][Full Text] [Related]
3. Combination of psoas muscle mass index and neutrophil-to-lymphocyte ratio as a noninvasive prognostic marker in hepatocellular carcinoma patients undergoing radiofrequency ablation.
Hayashi M; Abe K; Fujita M; Takahashi A; Ohira H
Eur J Gastroenterol Hepatol; 2023 May; 35(5):568-574. PubMed ID: 37115983
[TBL] [Abstract][Full Text] [Related]
4. Low Psoas-Muscle index is associated with decreased survival in hepatocellular carcinoma treated with transarterial chemoembolization.
Zhang JX; Yan HT; Ding Y; Liu J; Liu S; Zu QQ; Shi HB
Ann Med; 2022 Dec; 54(1):1562-1569. PubMed ID: 35639492
[TBL] [Abstract][Full Text] [Related]
5. The neutrophil-to-lymphocyte ratio is a predictive factor for the survival of patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
Wang C; Wang M; Zhang X; Zhao S; Hu J; Han G; Liu L
Ann Transl Med; 2020 Apr; 8(8):541. PubMed ID: 32411764
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma.
Liu BJ; Gao S; Zhu X; Guo JH; Zhang X; Chen H; Wang XD; Yang RJ
World J Gastrointest Oncol; 2020 Jun; 12(6):663-676. PubMed ID: 32699581
[TBL] [Abstract][Full Text] [Related]
7. Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101.
He CB; Lin XJ
PLoS One; 2017; 12(3):e0174769. PubMed ID: 28355305
[TBL] [Abstract][Full Text] [Related]
8. Skeletal muscle volume loss during transarterial chemoembolization predicts poor prognosis in patients with hepatocellular carcinoma.
Fujita M; Takahashi A; Hayashi M; Okai K; Abe K; Ohira H
Hepatol Res; 2019 Jul; 49(7):778-786. PubMed ID: 30884044
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment Neutrophil-to-Lymphocyte Ratio as Prognostic Biomarkers in Patients with Unresectable Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab.
Xiao Y; Zhu G; Xie J; Luo L; Deng W; Lin L; Tao J; Hu Z; Shan R
J Hepatocell Carcinoma; 2023; 10():2049-2058. PubMed ID: 37965074
[TBL] [Abstract][Full Text] [Related]
10. Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status.
Kodama K; Kawaoka T; Aikata H; Uchikawa S; Inagaki Y; Hatooka M; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Masaki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K
J Gastroenterol Hepatol; 2018 Oct; 33(10):1780-1786. PubMed ID: 29645345
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of lenvatinib combined with camrelizumab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A two-center retrospective study.
Sun B; Zhang L; Sun T; Ren Y; Cao Y; Zhang W; Zhu L; Guo Y; Gui Y; Liu F; Chen L; Xiong F; Zheng C
Front Oncol; 2022; 12():982948. PubMed ID: 36172158
[TBL] [Abstract][Full Text] [Related]
12. Blood neutrophil to lymphocyte ratio as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy.
Terashima T; Yamashita T; Iida N; Yamashita T; Nakagawa H; Arai K; Kitamura K; Kagaya T; Sakai Y; Mizukoshi E; Honda M; Kaneko S
Hepatol Res; 2015 Sep; 45(9):949-959. PubMed ID: 25319848
[TBL] [Abstract][Full Text] [Related]
13. Systemic inflammatory response predicts poor prognoses in Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma with transarterial chemoembolization: a prospective study.
Huang Z; Lu W; Yu N; Yang G; Xu H; Liu H
Transl Cancer Res; 2019 Nov; 8(7):2552-2563. PubMed ID: 35117012
[TBL] [Abstract][Full Text] [Related]
14. Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to Deep Response in Hepatocellular Carcinoma Treated with Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy.
Kuroda H; Oikawa T; Ninomiya M; Fujita M; Abe K; Okumoto K; Katsumi T; Sato W; Igarashi G; Iino C; Endo T; Tanabe N; Numao H; Fukuda S; Iijima K; Masamune A; Ohira H; Ueno Y; Takikawa Y
Liver Cancer; 2022 Jul; 11(4):383-396. PubMed ID: 35978602
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of hepatic arterial infusion chemotherapy with raltitrexed and oxaliplatin post-transarterial chemoembolization for unresectable hepatocellular carcinoma.
Liu B; Zhu X; Gao S; Guo J; Wang X; Cao G; Zhu L; Liu P; Xu H; Chen H; Zhang X; Liu S; Kou F
J Interv Med; 2019 May; 2(2):91-96. PubMed ID: 34805879
[TBL] [Abstract][Full Text] [Related]
16. The prognostic role of controlling nutritional status and skeletal muscle mass in patients with hepatocellular carcinoma after curative treatment.
Tamai Y; Iwasa M; Eguchi A; Shigefuku R; Sugimoto R; Tanaka H; Kobayashi Y; Mizuno S; Nakagawa H
Eur J Gastroenterol Hepatol; 2022 Dec; 34(12):1269-1276. PubMed ID: 36317773
[TBL] [Abstract][Full Text] [Related]
17. A combination of the preoperative neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios as a useful predictor of survival outcomes following the transarterial chemoembolization of huge hepatocellular carcinoma.
Liu J; Zhang W; Niu R; Li Y; Zhou X; Han X
Saudi Med J; 2020 Apr; 41(4):376-382. PubMed ID: 32291424
[TBL] [Abstract][Full Text] [Related]
18. Systemic Chemotherapy for Advanced Hepatocellular Carcinoma in Patients With Child-Pugh class B.
Kuwano A; Yada M; Tanaka K; Koga Y; Nagasawa S; Masumoto A; Motomura K
Cancer Diagn Progn; 2024; 4(2):111-116. PubMed ID: 38434920
[TBL] [Abstract][Full Text] [Related]
19. Neutrophil/lymphocyte ratio as a prognostic indicator of hepatic arterial infusion chemotherapy with arterial cisplatin plus continuous 5-fluorouracil.
Tajiri K; Kawai K; Minemura M; Yasumura S; Hosokawa A; Kawabe H; Tomizawa G; Sugiyama T
Hepatol Res; 2015 Jul; 45(7):755-63. PubMed ID: 25196816
[TBL] [Abstract][Full Text] [Related]
20. A Novel Neutrophil-to-Lymphocyte Ratio and Sarcopenia Based TACE-Predict Model of Hepatocellular Carcinoma Patients.
Wang S; Zhang X; Chen Q; Jin ZC; Lu J; Guo J
J Hepatocell Carcinoma; 2023; 10():659-671. PubMed ID: 37113464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
